Please ensure Javascript is enabled for purposes of website accessibility

2 Top Global Value Stocks to Buy Now

By Zhiyuan Sun - Jul 8, 2021 at 5:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Don't want to pay too steep a price for high-quality stocks? Look abroad.

The S&P 500 has reached record levels while delivering a mouthwatering 43% return since last July. As spectacular as this rally has been, it has priced out many investors who were late to the game. The index is now trading at a price-to-earnings (P/E) ratio of 46 -- its second most expensive valuation in history (and just below its level from the 2008 financial crisis!).  

But that doesn't mean all stocks are expensive. To find great bargains, one could look abroad and into the realm of American Depository Receipts (ADRs). So let's have a look at the top foreign stocks to buy now. 

Businesspeople in meeting with virtual participant.

Image source: Getty Images.

1. Qiwi

Qiwi (QIWI 9.88%) is a leading payment solutions provider in Russia and much of the former Soviet Union. Apparently (according to the company), opening up a digital wallet on Qiwi is easier than tying one's shoelace -- all one needs is a phone number. There is no identity verification required, and the fees are low, if not zero. The company boasts of having more than 29 million customers and processes more than 128 billion rubles ($1.75 billion) worth of transactions each month.

It also manages more than 106,000 kiosks (ATMs) in the aforementioned geographical regions, where customers can deposit cash into their digital wallets. Don't regard this as a small detail; many former Soviet states still operate as cash-based economies. After all, capitalism has only been around in these countries since 1991. Cash is still king (or tsar, Putin, etc.) there.

But know that Qiwi is here to stay for the long term. For historical and political reasons, many Russian consumers are rather skeptical of Western-based tech firms (and I don't blame them!). Instead, they would prefer made-in-Russia alternatives, such as instead of Facebook, and searching on Yandex instead of Google. 

Or better yet, take the example of Paypal (PYPL 2.01%). The payment solutions giant has been in Russia since 2006 but recently terminated domestic money transfers between Russian users, citing unpopularity. It looks like the charm runs deep within Qiwi. 

The company has its own line of credit cards in addition to managing digital payments. What's more, it offers up to 8% cash back for its customers for shopping on e-commerce sites like AliExpress. More than 630,000 users have signed up for the bonus.

Despite all it has to offer, the stock is ridiculously cheap at just 6.4 times forward earnings. For future growth, I would look at growing integration between e-commerce retailers and its own users. This is a top-notch payment solutions provider you don't want to miss. 

2. Dr. Reddy's Laboratories 

Dr. Reddy's Laboratories (RDY 0.98%) is a global generic pharmaceuticals company that has been at the forefront of combating the COVID-19 pandemic in India. The country happens to be the world's largest vaccine manufacturer, with the (privately owned) Serum Institute of India being able to make 2 billion doses of coronavirus vaccine per year and deliver them through government partnerships.

However, the Indian government, led by Prime Minister Narendra Modi, exported much of its vaccines abroad during Q1 2021, citing a low number of coronavirus cases. That decision has now backfired, as the rampant spread of the deadly delta variant has wreaked havoc on the country.

This has created a situation in which India must rely on the import of coronavirus vaccines to keep the pandemic under control. In May, Dr. Reddy's secured exclusive marketing and distribution rights for the first 250 million doses of Russia's Sputnik V vaccine (91.6% effective against COVID-19). Analysts estimate the agreement could bring over $300 million in revenue for the company -- in addition to alleviating the pandemic.

What's more, the company also received the green light from Gilead Sciences (GILD 0.82%) to make its COVID-19 drug, remdesivir. Simultaneously, it began supplying its own COVID-19 treatment, Drug 2-DG, to government agencies and private hospitals in June. 

The company is also doing well outside of India. On June 22, it began launching its own version of Vascepa, a fish oil fat used to treat high glyceride levels and reduce the risk of cardiovascular diseases. In 2020, the branded version of Vascepa brought in $590 million in sales.  

During the past four years, the company has consistently grown its revenue by about 10% per year, to $2.6 billion in fiscal 2021 (ended March 31). At the same time, its free cash flow has stayed consistent at $300 million per year. Dr. Reddy's cash balance also outranks its debt, giving it no financial leverage.

It markets about 300 generics and six biosimilars worldwide, with 12 drugs in clinical trials. Overall, Dr. Reddy's stock is trading for about 25 times forward earnings, which is pretty cheap considering its COVID-19 treatment and generic Vascepa offering could send its financials soaring. So this is definitely one of the top pharma stocks to buy now. 

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Facebook, PayPal Holdings, and Yandex. The Motley Fool recommends Gilead Sciences and recommends the following options: long January 2022 $75 calls on PayPal Holdings. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
$53.64 (0.98%) $0.52
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$180.50 (1.70%) $3.01
Yandex N.V. Stock Quote
Yandex N.V.
$18.94 (-6.79%) $-1.38
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51
Qiwi plc Stock Quote
Qiwi plc
$5.67 (9.88%) $0.51
PayPal Holdings, Inc. Stock Quote
PayPal Holdings, Inc.
$101.10 (2.01%) $1.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.